Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Here, we describe a combined flow cytometric cell sorting and low-input, next-generation library construction protocol designed to produce high-quality, whole-exome data from the Hodgkin Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (CHL).

Abstract

The Hodgkin Reed-Sternberg cells of classical Hodgkin lymphoma are sparsely distributed within a background of inflammatory lymphocytes and typically comprise less than 1% of the tumor mass. Material derived from bulk tumor contains tumor content at a concentration insufficient for characterization. Therefore, fluorescence activated cell sorting using eight antibodies, as well as side- and forward-scatter, is described here as a method of rapidly separating and concentrating with high purity thousands of HRS cells from the tumor for subsequent study. At the same time, because standard protocols for exome sequencing typically require 100-1,000 ng of input DNA, which is often too high, even with flow sorting, we also provide an optimized, low-input library construction protocol capable of producing high-quality data from as little as 10 ng of input DNA. This combination is capable of producing next-generation libraries suitable for hybridization capture of whole-exome baits or more focused targeted panels, as desired. Exome sequencing of the HRS cells, when compared against healthy intratumor T or B cells, can identify somatic alterations, including mutations, insertions and deletions, and copy number alterations. These findings elucidate the molecular biology of HRS cells and may reveal avenues for targeted drug treatments.

Introduction

Advancements in cancer genomics as a result of next-generation sequencing have led to significant breakthroughs in the identification of therapeutic targets and in prognostication for many hematologic and non-hematologic neoplasms. New individualized treatment strategies based on specific genomic alterations are rapidly being introduced in many tumor types (reviewed in references1,2). Despite significant progress in lymphoma genomics, the genome of the neoplastic HRS cells in classical Hodgkin lymphoma (CHL) had been underexplored. The investigations have been hampered by the scarcity of neoplastic HRS cells w....

Protocol

1. Tissue Processing and Freezing

  1. Collect lymph node tissue in phosphate-buffered saline (PBS) or Roswell Park Memorial Institute medium (RPMI) and process within 24 h of collection. Transfer excised lymph node tissue9 to a Petri dish containing 10 mL of RPMI with 2% fetal calf serum (FCS) and finely mince it with a fresh scalpel blade. Use the back of a 10-mL syringe plunger to further grind/dissociate the tissue.
  2. Transfer the liquid to a 50-mL conical tube through a 100 .......

Representative Results

A bioanalyzer plot should be taken after library amplification and 0.8x bead cleanup. One should see a "normal-like" distribution of fragment sizes in the desired range (Figure 2a). Deviations from this shape, such as a visible "shoulder" in the curve, indicate the presence of a high or low molecular weight artifact. For example, Figure 2b-2d shows examples of libraries containing visible artifact.......

Discussion

Future applications or directions after mastering this technique

This work allows for exome sequencing from samples containing at least 10 ng of DNA. In the clinical context, this limit excludes most fine-needle aspiration samples due to insufficient material, but it includes adequate core biopsies and excisional biopsy samples. This will enable the acquisition of data from a larger set of possible samples.

Critical steps within the protocol.......

Acknowledgements

The development of this project method was funded by the Department of Pathology and Laboratory Medicine of Weill Cornell Medical College. We acknowledge the Tri-Institutional Training Program in Computational Biology and Medicine for partial funding. We would like to thank the scientists who shared their time and knowledge with us, especially Maryke Appel; Dan Burgess; Iwanka Kozarewa; Chad Locklear; and everyone from the Weill Cornell Medical College Genomics Core Facility, including Jenny Zhang, Xiaobo (Shawn) Liang, Dong Xu, Wei Zhang, Huimin Shang, Tatiana Batson, and Tuo Zhang.

....

Materials

NameCompanyCatalog NumberComments
Petri or Cell Culture Dish (sterile)
RPMI-1640 MediaRoswell Park Memorial Institute
Fetal Calf Serum (FCS), (heat inactivated)
Freezing Media (RPMI, 20% FCS, 10% dimethylsulfoxide (DMSO))-make fresh and keep sterile
RPMI with 2% FCS (make fresh or store for up to 1 month)
scalpel with fresh blade
10 ml syringe (no needle)
Cryogenic vials
50 ml conical centrifuge tubes, force
Centrifugecapable of handling 50 ml conical centrifuge tubes and providing 400g
Hepes buffer(1M, cell culture grade)
phosphate buffered saline (PBS)
Pluoronic-F68Thermo-Fisher24040-032
DNAase-ISigma-Aldrich, St. Louis, MOD4527-10KUstore as 5mg/ml in RPMI in -200C
Bovine Serum Albumin (BSA)
Sort Media (PBS+2%BSA+25mM HEPES+ Pluoronic –F68 (1X))
CD64-FITC (22)Beckman Coulter, Miami, FL20 uL suggested starting volume; Titering is suggested
CD30-PE (BerH83)BD Biosciences, San Jose, CA20 uL suggested starting volume; Titering is suggested
CD5-ECD (BL1a)Beckman Coulter, Miami, FL10 uL suggested starting volume; Titering is suggested
CD40-PerCP-eFluor 710 (1C10)Ebiosciences, San Diego, CA5 uL suggested starting volume; Titering is suggested
CD20-PC7 (B9E9)Beckman Coulter, Miami, FL10 uL suggested starting volume; Titering is suggested
CD15-APC (HI98)BD Biosciences, San Jose, CA20 uL suggested starting volume; Titering is suggested
CD45 APC-H7 (2D1)BD Biosciences, San Jose, CACan be substituted with 10 uL suggested volume of CD45-Krome Orange (J.33, Beckman Coulter); Titering is suggested
CD95-Pacific Blue (DX2)Life Technologies, Grand Island, NY5 uL suggested starting volume; Titering is suggested
CD2 (5 μg; clone RPA-2.10)Biolegend, San Diego, CAFor optional protocol; Titering is suggested
CD54 (10 μg; clone 84H10)Serotec, Oxford, United KingdomFor optional protocol; Titering is suggested
CD58 (10 μg; clone TS2/9)eBioscience, San Diego, CAFor optional protocol; Titering is suggested
LFA-1 (12 μg; clone MHM23)Novus Biologicals, Littleton, COFor optional protocol; Titering is suggested
BD CS&T BeadsBD Biosciences, San Jose, CA
BD Accudrop BeadsBD Biosciences, San Jose, CA
BC Versa Comp antibody capture beadsBeckman Coulter, Miami, FLCompensation Beads
BD-FACS ARIA special research order instrument using 5 lasersBD Biosciences, San Jose, CAany BD-FACS aria with capabilities to detect the fluorochromes in the antibody panel should be sufficient
WizardPromegaA2360
10 mM Tris-Cl bufferNA
Qubit dsDNA HS Assay kitLife Technologies, Carlsbad, CA
S2 SonicatorCovaris, Woburn, MAAlternatives may be substituted
microTUBECovaris, Woburn, MA
Low-Throughput Library Preparation KitKapa Biosystems, Wilmington, MAKK8221
Sybr GreenSigma-Aldrich, St. Louis, MOS9430
Agencourt AMPure XP BeadsBeckman Coulter, Miami, FL
BioanalyzerAgilent Technologies, Santa Clara, CA
SeqCap EZ Exome v.3.0Roche Nimblegen6465684001
HiSeqIllumina
TruSeq-style Universal adapterIntegrated DNA Technologies (IDT), Coralville, IowaHPLC purification; AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGAT*C*T
TruSeq-style index adapterIntegrated DNA Technologies (IDT), Coralville, IowaHPLC purification; /5Phos/GATCGGAAGAGCACACGTCTGAACTCCAGTCACNNNNNNATCTCGTATGCCGTCTTCTGCTTG
TruSeq-style PCR primer 1Integrated DNA Technologies (IDT), Coralville, IowaAATGATACGGCGACCACCGAGA
TruSeq-style PCR primer 2Integrated DNA Technologies (IDT), Coralville, IowaCAAGCAGAAGACGGCATACGAG
Nuclease Free Duplex BufferIntegrated DNA Technologies (IDT), Coralville, Iowa
BD FACSDIVA softwareBD Biosciences, San Jose, CA
BD Falcon TubesBD Biosciences, San Jose, CA
BD Flow TubesBD Biosciences, San Jose, CA

References

  1. Abrams, J. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. , 71-76 (2014).
  2. Gagan, J., Van Allen, E. M.

Explore More Articles

Flow sortingExome SequencingReed Sternberg CellsClassical Hodgkin LymphomaCHLHRS CellsNext generation SequencingTumor derived DNADiagnosisClassificationPrognosisTherapyFlow CytometryAntibody CocktailThawing MediumSorting Medium

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved